Concert Pharmaceuticals
Lexington
About Concert Pharmaceuticals
Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $271.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2022)
- Ticker: nasdaq:CNCE
- Website: concertpharma.com
- Phone: 7816745322
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/concert-pharmaceuticals-162561 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.